FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|November 9, 2021
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of November 9, 2021
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the
How many people in the US have been vaccinated against COVID-19?
According to the CDC as of today, November 9, 2021, at 2:33 PM, EDT:
• 67.5% of total US population has received at least 1 dose
• 58.5% of total US population is fully vaccinated
• 58.5% of total US population is fully vaccinated
The 5 states/territories with the highest percentage of population fully vaccinated are:
1. Puerto Rico: 73.9%
2. Vermont: 71.8%
3. Rhode Island:71.4%
4. Maine: 71.2%
5. Connecticut: 71.1%
2. Vermont: 71.8%
3. Rhode Island:71.4%
4. Maine: 71.2%
5. Connecticut: 71.1%
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, November 9, 2021 at 3:21 PM, EDT, there have been:
• 46 661 243 confirmed cases and
• 756 574 deaths
• 756 574 deaths
The 5 states with the highest total confirmed cases are:
1. California: 4 979 715
2. Texas: 4 268 102
3. Florida: 3 701 310
4. New York: 2 595 315
5. Illinois: 1 722 590
2. Texas: 4 268 102
3. Florida: 3 701 310
4. New York: 2 595 315
5. Illinois: 1 722 590
Deaths: California has the highest number of deaths due to COVID-19 with 72 676 reported fatalities, followed by Texas with 72 107 and Florida with 60 418.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 250 707 063 confirmed cases, 5 061 810 deaths, and 7 308 859 304 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5